Delphine Collin, Ph.D.

Senior Vice President, Head of Drug Discovery

Delphine Collin brings more than 20 years of small molecule drug discovery and preclinical development experience to Sonata Therapeutics.

Before joining Sonata, Delphine served as VP of Platform and External Innovation at Faze Medicine, where she integrated multiple disciplines and approaches to study and drug condensates. As VP of Biomolecular Sciences at Cedilla Therapeutics, she led cross-functional early discovery activities from target identification to lead delivery. Prior to that, at Boehringer Ingelheim, Delphine led small molecule programs to stage-gate transitions, including IND filing. She started her career at Merck & Co. where she pioneered the use of label-free technologies.

Delphine is a recognized scientific leader with a proven track of record of cultivating innovation and developing successful discovery strategies. She leads high-performing teams across disciplines to deliver on goals.

Delphine holds a Ph.D. in Physical Chemistry and a Pharm.D. both from the University of Paris XI in France.

Scroll to Top